Spots Global Cancer Trial Database for The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
Official Title: TME vs TME+nCT in Low-risk LARC
Study ID: NCT05984485
Conditions
Study Description
Brief Summary: Comparative analysis of the clinical efficacy between primary Total Mesorectal Excision (TME) surgery and neoadjuvant chemotherapy combined with TME surgery for low-risk locally advanced rectal cancer. Randomly enrolling eligible patients into either the control group receiving neoadjuvant chemotherapy combined with TME surgery or the experimental group receiving primary TME surgery, and subsequently comparing the clinical outcomes of the two groups
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Daping Hospital, Amy Medeical Univerisity, Chongqing, Chongqing, China
Sun yat-sen University, the Sixth Affiliated Hospital, Guangzhou, Guangdong, China
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
Contact Details
Name: Liang Kang, PhD,MD
Affiliation: Sun yat-sen University, sixth affiliated hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
